



Multidisciplinary International Group for Hemapheresis TherapY and MEtabolic Disturbances Contrast

19th Lipid Club and Therapeutic Apheresis

2024 Edition

PRELIMINARY PROGRAMME

MIGHTY MEDIC Org.'s Advanced Clinical Major Seminary and Educational Forum on Clinical Lipidology, Metabolic Disorders, Extracorporeal Therapeutic Techniques, and Atherosclerosis Prevention

Seminario Clinico Avanzato e formazione continua in Lipidologia Clinica, Disturbi del Metabolismo, Tecniche Terapeutiche Extracorporee e Prevenzione dell'Aterosclerosi

Meeting venue: Hall of the Hospital – P. Pederzoli – Peschiera del Garda

Peschiera del Garda, Italy, April 18-19, 2024



Ospedale P. Pederzoli



Peschiera del Garda

Hall: P. Pederzoli Hospital

Thursday, April 18, 2024 - Afternoon

14.30 INTRODUCTORY REMARKS – CENNI INTRODUTTIVI

Claudia STEFANUTTI, Maria Grazia ZENTI

=====

14.40

1st SESSION

Thursday, April 18, 2024 - Afternoon

Language: English (*slides in English are mandatory*)

CLINICAL PRACTICE - DIAGNOSIS AND TREATMENT (I)

HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA

14.40 Chairpersons: Livia PISCIOTTA, Claudia STEFANUTTI

New insights in the genetics of Homozygous Familial Hypercholesterolaemia

14.40 *Livia PISCIOTTA (20')*

Existing and Emerging Therapies for Homozygous Familial Hypercholesterolaemia

15.00 *Maria Grazia ZENTI (20')*

LDLR – Independent Novel Lipid Lowering Drugs for treating Homozygous Familial Hypercholesterolaemia

15.20 *Claudia STEFANUTTI (20')*

15.40 **Discussion (15')**

CLINICAL PRACTICE - DIAGNOSIS AND TREATMENT (II)

SEVERE DYSLIPIDAEMIA IN PEDIATRICS

15.55 Chairpersons: Kurt WIDHALM, Alexandre BIDAN

Familial Hypercholesterolaemia in children and adolescents

15.55 *Kurt WIDHALM (20')*

Different therapeutic approaches for pediatric Homozygous Familial Hypercholesterolaemia (HoFH). Is today the time for novel drugs?

16.15 *Elena FORNARI (20')*

CLINICAL PRACTICE - DIAGNOSIS AND TREATMENT (III)

NOVEL LIPID LOWERING DRUGS

16.35 Chairpersons: Paolo BAZZONI, Maria Grazia ZENTI

PCSK9 Inhibitors. State of the art

16.35 *Elisabetta RINALDI (20')*

Inclisiran. Update

16.55 *Elena SANI (20')*

17.15 **Discussion (15')**

17.30 **End of the 1st SESSION**

08.30

2nd SESSION

Friday, April 19, 2024 - Morning

Language: Italian and English

CLINICAL PRACTICE - DIAGNOSIS AND TREATMENT (IV)

CARDIOLOGY – HIGH CV RISK

08.30 Chairpersons: Filippo LEONARDO, Maria Grazia ZENTI

08.30 The patient with peripheral vascular disease and ischemic diabetic foot

08.30 *Cristian NICOLETTI (20')*

Is HyperLp(a) lipoproteinemia in diabetic patients primary or secondary?

08.50 *Cristina BITTANTE (20')*

09.10 **Discussion (10')**

CLINICAL PRACTICE - DIAGNOSIS AND TREATMENT (V) *First Half*

BLOOD COMPONENT REMOVAL, THERAPEUTIC APHERESIS, LIPOPROTEIN APHERESIS

09.20 Chairpersons: Yuri BATTAGLIA, Milco CICCARESE, Maria COSSU

Pregnancy treatment and outcome in HoFH women. A novel positive experience with Lipoprotein Apheresis.

09.20 *Giuseppina PERRONE (20')*

Lipoprotein apheresis to treat elevated lipoprotein (a)

09.40 *Milco CICCARESE (20')*

10.00 **Discussion (10')**

10.10 **Coffee Break (20')**

Second Half

Novel International Guidelines on Lipoprotein Apheresis

10.30 *Giancarlo LABBADIA (20')*

Refractory Severe Hypertriglyceridaemia. What can Therapeutic Apheresis do?

10.50 *Antonio VIVENZIO (20')*

11.10 **Discussion (10')**

EXPERT COMMUNICATIONS (Discussion at the end of each communication)

11.20 **Chairpersons:** Kurt WIDHALM, Giuseppina PERRONE

11.20 _ Epigenetics in Obesity

Antonio VIVENZIO (10+5')

11.35 _ Obesity in Childhood

Luigi TARANI (10+5')

11.50 _ The clinical experience of the cardiologist in severe dyslipidaemia

Jasmine KASSEM (10+5')

12.05 _ EuroQol (EQ-5D-3L) questionnaires on Evinacumab impact in Patients with Homozygous Familial Hypercholesterolaemia

Giovanna ZEPPA, Claudia STEFANUTTI (10+5')

12.20 _ Management of a young HoFH woman during pregnancy using Lipoprotein Apheresis (Whole Blood). A novel experience and our thoughts.

Giovanna ZEPPA, Elisabetta AGUS, Giuseppina PERRONE (10+5')

MIGHTY MEDIC ORG. GENERAL ASSEMBLY

12.35 Chairpersons: Claudia STEFANUTTI, Livia PISCIOTTA, Maria COSSU, Maria Grazia ZENTI

MIGHTY MEDIC ORG. 2024. Touch base.

12.35 *Claudia STEFANUTTI (10')*

12.45 General discussion and concluding remarks (15')

13.00 **CME Credits ITALY - WRAP UP**

SCIENTIFIC SECRETARIAT

Professor Claudia Stefanutti M.D., Ph.D. Head of Extracorporeal Therapeutic Techniques Unit Lipid Clinic and Atherosclerosis Prevention Centre - Department of Molecular Medicine "Sapienza" University of Rome. Responsabile del Centro Regionale (Lazio) Tecniche Terapeutiche Extracorporee - Gravi Dislipidemie Genetiche - Dipartimento di Medicina Molecolare "Sapienza" Università di Roma "Policlinico Umberto I" - Viale del Policlinico 155 - Rome Italian Multicenter Study on LDL-apheresis Working Group Coordinator - Coordinatrice dello Studio Multicentrico Italiano LDL Aferesi (SMILDLA) - MIGHTY MEDIC - Multidisciplinary International Group for Hemapheresis Therapy and Metabolic Disturbances Contrast, President. 155, V.le del Policlinico –

Rome, Italy 00161 Tel. 06 499 70578 – Fax 06 499 70141 - claudia.stefanutti@uniroma1.it
www.mightymedic.org

and

Maria Grazia Zenti, M.D., Ph.D. Specialista in Endocrinologia, Diabetologia e Malattie del Ricambio
Responsabile del Servizio di Diabetologia e Malattie Metaboliche - "Ospedale P. Pederzoli" - Casa
di Cura Privata S.p.A. Via Monte Baldo 24, 37019 Peschiera del Garda, VR
tel: 045 6449 214- 215 - E-mail: mgzenti@gmail.com; mariagrazia.zenti@ospedalepederzoli.it;
www.ospedalepederzoli.it

CME For Italian Participants: Congress will participate at Continuing Medical Education for the following categories: internal medicine, metabolic diseases and diabetology, pediatrics, transfusion medicine, hematology, nephrology, cardiology, gynecology, ophthalmology, gastroenterology, nurses, technicians of cardiocirculatory physiopathology and cardiovascular perfusion.

Avviso a Speakers e Moderatori: la partecipazione al meeting dovrà essere obbligatoriamente in persona. Non saranno accolte videoregistrazioni e presentazioni da remoto.

Notice to Speakers and Chairs: participation in the meeting must be in person. Video recordings and remote presentations will not be accepted.

PRELIMINARY PROGRAMME